Lymphokine-mediated bone resorption requires endogenous prostaglandin synthesis by unknown
BriefDefinitive Report
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Localized bone loss can be associated with certain inflammatory, hypermetabolic,
and neoplastic diseases. The pathogenesis of osteolytic lesions in most of the latter
conditions has not been elucidated. Lymphocytes have been shown to release factor(s)
with osteolytic activity (1-3) . One lymphokine, osteoclast activating factor (OAF), a
product of T or B lymphocytes, has in part been chemically characterized (4-7) .
Bioassays have not been able to distinguish osteoclast-mediated bone resorption
initiated by parathyroid hormone (PTH) from that caused by OAF. Both agents
cause the release of calcium from bone with similar dose-dependency curves (8), both
cause osteoclast activation as measured by increased cell number and size (9), and
both agents activate adenylate cyclase in bone cells (10, 11) . We therefore decided to
look more closely at the sequence of biochemical events that occurs during lympho-
kine-mediated bone resorption. In particular, we examined endogenous bone synthesis
and release of prostaglandins after exposure to a lymphokine preparation that
probably contained OAF activity.
Materials and Methods
Prostaglandin Synthesis by Explanted Fetal Rat Bone Culture.
￿
The radii and ulnae from 20-d-old
fetal rats were placed into culture as previously described (8) . The classes of prostaglandins
synthesized by the explanted bones were followed by measuring the conversion of tritiated
arachidonic acid ([5, 6, 8, 9, 11, 12, 14, 153H]arachidonic acid, Amersham Corp., Arlington
Heights, Ill.) and by radioimmunoassay, as previously described for monocytes and macro-
phages (12, 13) .
Bone Calcium Release.
￿
To measure calcium release from bone, the fetal rat bones were labeled
in utero by injecting the mother with 0.2-0.4 MCi of 45CaC12 on the 18th d of gestation (8) .
Calcium release was determined by counting the supernate media in a liquid scintillation
counter; the data are expressed as the ratio ofcalcium release in counts per minute (cpm) of the
experimental bone per cpm released by the paired control bone (E:C) .
Preparation ofLymphokine.
￿
Lymphokine-containing media was prepared from human periph-
eral blood mononuclear cells that had been isolated by differential centrifugation (12, 13).
McCoy's 5A media supplemented with 10% heat-inactivated fetal calf serum was conditioned
by 5 million cells/ml in the presence of 2.5 ,ug/ml phytohemagglutinin (PHA; Wellcome
Research Laboratories, Kent, Great Britain) for 24-48 h at 37° C in a humidified 5% C02
atmosphere. The cell-free media was harvested and frozen at -80°C until tested in the bone
cultures. The bone resorbing activity of the lymphokine-containing media was retained at
neutral pH by a dialysis membrane having a 6,000-8,000 mol wt cutoff (Spectrapor TM,
Spectrum Medical Industries, Inc., Los Angeles, Calif.), which is similar to previous findings
with OAF (7). Measurement of prostaglandin (PG)E levels in the lymphokine-containing media
showed it to have <10% of the levels released by fetal rat bones (8). Therefore, the aliquots of
lymphokine added to the bone cultures could not have contributed significantly to the PGE
levels measured in the explanted bone culture supernates.
* Supported by grant Pdt-60C from The American Cancer Society and grant CA-23500 from The
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Reagents.
￿
Purified PTH was prepared by Sephadex column chromatography from urea-
HCI-cysteine, trichloroacetic-precipitated bovine parathyroid gland extracts (14) .
Results and Discussion
Bones that had been radiolabeled with arachidonic acid released several classes of
tritiated prostaglandins (Table I) . Lymphokine-stimulated bones showed a marked
and selective increase in [3H]PGE2 release (Table I). Indomethacin and flurbiprofen,
structurally unrelated cyclooxygenase inhibitors, markedly reduced the amount of
[3H]PGE2 released by lymphokine-stimulated bones. Greater than 85% of the
[3H]arachidonic acid could be recovered from the bones by chloroform-methanol
extraction at the end of the 96-h culture. A similar release pattern and quantitative
increase in [3H]PGE2 was seen if a bacterial endotoxin was substituted for lymphokine
(data not shown). PGE levels measured in bone by radioimmunoassay showed a
highly significant correlation, P < 0.001 with [3H]PGE2 release (r = 0.91, n = 19).
Such correlation would suggest that tritiated arachidonic acid conversion to [3H]-
PGE2 adequately reflects PGE-synthetase activity. It is not known whether such a
correlation exists for the other prostaglandins because their absolute levels were not
measured.
A comparison of the dose-dependent release of PGE and
45Ca
by the explanted
bones that had been exposed to the test agents was made. Lymphokine-induced PGE
levels were significantly greater than control or PTH-treated bones (P < 0.001) at all
concentrations tested (Fig. 1 A and B) . PHA alone had no significant effect on PGE
or 45Ca release.
When PGE synthesis was followed as a function of time in culture, a characteristic
sequence of biochemical events was seen. Similar levels of PGE were released from
bones equilibrating in control media; (Fig. 2; mean PGE release ± SEM from 36
bones after the first 18 h in culture was 1 .13 ± 0.07 ng/bone). At the end of a 24-h
exposure to lymphokine, bone PGE synthesis showed a 20-fold increase compared
with untreated bones (20.55 ± 1 .05 vs. 1 .05 ± 0.1 ng/bone) for the experiment shown.
Four separate experiments gave similar results, and, in every case, the addition of
structurally unrelated prostaglandin-synthetase inhibitors caused a significant de-
TABLE I
Tritiated Prostaglandin Releasefrom Explanted Fetal Rat Bones
indomethacin
* Each plate represents the pooled, extracted supernatant media from four cultured bones.
$ Significantly greater than control (P < 0.02) as determined by the t test for two means. After an 18-h
equilibration period, two pairs of ulnae and radii per culture were incubated with 10 [LCi of [3H]-
arachidonic acid for 4-6 h. The nonincorporated label was removed by washing with fresh media. The
bones were then incubated for 24 h with fresh media (control) or with media that contained bovine PTH
(2.0 gM final concentration) or 0.3 ml of lymphokine. At the 48th h of culture (representing 24 h of
continuous exposure to the test substances), the media was removed from the bone cultures and analyzed
for the tritiated prostaglandin conversion products. The tritiated Prostaglandins were separated by two-
dimensional thin-layer chromatography on silica gel plates (12, 13). Abbreviations used : PGF2a, 6K-
PGF,o, PGE2, and TXB2 for prostglandins F2a, 6-keto Fl, E2, and thromboxane B2, respectively.
Num- Mean cpm [3H]prostaglandin released ± SEM/plate
Test substance ber of
plates* PGF2q 6K-PGF,~ PGE2 TXB2 Arachidonic acid
Control 5 113 t 40 134 ± 21 348 ± 94 92 ± 36 69,884 t 18,140
PTH 2 31 56 406 42 52,302
Lymphokine 3 313 ± 48$ 179 ± 33 6,554 ± 2,547$ 133 t 10 47,145 t 4,988
Lymphokine + 1 117 187 102 123 52,381d
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FIG. 1.
￿
Dose-dependent release of PGE (A) and 'Ca (B) from explanted fetal rat bones treated in
culture with PTH (") or lymphokine (O). PTH was tested from 0.01 to 10 AM final concentration;
aliquots of a lymphokine-containing media conditioned by 5 million mononuclear cells/ml in the
presence ofPHA. Data given as the mean (n = 4) ± SEM of the ratio counts per minute (cpm)
45Ca
released from experimental bones/cpm 45Ca released from paired control bones (E:C). Mean PGE
release by 32 control bones t SD = 0.9 t 0.3 ng/bone; mean E:C for 24 control bones t SEM =
1.0 t 0.03. PHA alone had no effect on PGE or 45Ca release from bones. * Significantly different
from controls (P < 0.001) as determined by t test of two means.532
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FIG . 2.
￿
The effect ofPTH and OAF on PGE and 45Ca release from fetal rat bones. (A) PGE levels
were measured by radioimmunoassay in the media conditioned by fetal rat bones after an initial
equilibration period (0-18 h), after 30 h in the presence oftest substances (18-48 h), and finally, 48
h after the removal of the test substances (48-96 h) . Each bar graph represents the mean t SEM of
at least six samples ; each sample represents one culture dish containing one bone . All data were
derived from a single representative experiment . (B) Release of
45Ca from the explanted bone
cultures was followed as a function of time . The fetal rat forelimb bones were derived from
littermates and the data are expressed as the ratio ofcounts per minute released by the experimental
bones divided by the mean ofthe six control bones in that particular test group (E:C) . ' Significantly
greater than control, P< 0.005 . $ Significantly greater than control, P< 0.001 .
crease in the levels ofPGE released, suggesting that de novo synthesis of prostaglandins
was being measured . For the experiment shown in Fig . 2, flurbiprofen (10 AM added
20 min before the test substance) caused a significant (P < 0.001) reduction in
lymphokine-induced PGE release measured at 48 h (21 .4 ± 1 .1 to 11.5 ± 1 .2 ng PGE
released/bone, n = 8) . Higher levels of flurbiprofen and indomethacin reduced PGE
release to control levels . No significant lowering ofPGE levels was noted in the control
or in PTH-treated bones .
Radiolabeled calcium release measured at the end ofculture (48 h after the removal
of the test substances) of both the PGE and lymphokine-treated bones showed
markedly enhanced calcium release as compared with control bones (E/C = 1 .64 ±
0.1 and 1 .45 ± 0.12, respectively, compared with 1 .0 ± 0.05, P < 0.005 ; Fig. 2) . In
every case studied (n =
5),45Ca release occurred with a delayed time-course compared
with that noted for PGE release and occurred after the removal of the stimulus from
the culture media . The concomitant administration of indomethacin or flurbiprofen
with PTH had no effect on the calcium release induced by PTH (E :C = 1.64 ± 0.1BOCKMAN AND REPO
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vs. 1.58 ± 0.11, n = 4 bones/experimental point) . In contrast, the addition of
prostaglandin-synthetase inhibitors with lymphokine significantly abrogated its abil-
ity to induce calcium release (E:C = 1 .45 ± 0.12 reduced to 1 .11 ± 0.08, P G 0.05).
The data strongly suggest that the early burst of PGE synthesis caused by lymphokine
was required for the subsequent calcium release.
The induction of bone prostaglandin synthesis by lymphokine is not a response
that is unique for that agent. Endotoxin as well as antigen-antibody plus complement
have been reported to cause increased calcium as well as PGE release from bone (15,
16) . In another model of localized bone loss, indomethacin could be shown to block
resorption caused by the application of gingival fragments to bone but not that
induced by PTH (17).
Bone resorption caused by inflammatory stimuli tends to be highly localized and
dependent on the secretion of locally produced factors. Prostaglandins are likely
mediators of inflammatory cell-induced bone resorption because they are locally
produced, have a short half-life in the circulation, and because continuous stimulation
is required to maintain locally elevated levels. Furthermore, prostaglandins are known
to amplify or even initiate several cell activities associated with bone resorption. They
can, for example, augment adenylate-cyclase activity in bone, which is a necessary
concomitant step in the factor-mediated bone resorption (10, 11, 18) . Alternatively,
prostaglandins can act by accelerating lysosomal enzyme release, which is necessary
for collagen matrix digestion and mineral dissolution to occur (19, 20) . Prostaglandin
synthesis and release after macrophage exposure to endotoxin has been shown to be
essential for neutral protease release from lysosomes (21) . Finally, prostaglandin
secretion by monocytes has been shown to be necessary for OAF release from
lymphocytes (22). Prostaglandins may thus be acting through a positive feedback loop
to maintain elevated OAF levels.
To our knowledge, initiation of prostaglandin synthesis is the first biochemical
response that clearly distinguishes lymphokine and PTH-stimulated bones. The
biochemical response of enhanced PGE synthesis could have several different roles in
facilitating inflammatory-factor-initiated bone resorption. Our data from explanted
fetal rat bones provide evidence that endogenous prostaglandin synthesis within bone
is necessary for lymphokine-induced bone resorption; the subsequent mechanisms by
which prostaglandins mediate bone mineral dissolution remain to be elucidated.
Summary
Enhanced synthesis of prostaglandin (PG)E by explanted fetal rat bones was
initiated by lymphocyte-conditioned media but not by physiological levels of para-
thyroid hormone. Rapid release of PGE from bone occurred only when the lympho-
kine was present. Synthesis ofPGE preceded and was necessary for the bone resorption
caused by the lymphokine preparation. Local production ofprostaglandins in response
to inflammatory cell or tumor-derived factors may in part be responsible for the
localized bone loss that occurs in certain pathological states.
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